Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Epivario Inc. is currently addressing 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This activity is distributed across 1 distinct examiner and 1 distinct art unit, showing a concentrated effort in a specific technical domain. The current state of the portfolio involves a singular interaction with the patent office, which simplifies the management of deadlines and examiner communications. This focused approach allows the applicant to address the specific requirements of 1 distinct art unit directly.
The busiest examiner for the company is FERGUSON, JALISA HOLMES, who is currently overseeing 1 pending office action. This 1 pending office action accounts for the total pending volume for Epivario Inc. at this time. With 1 distinct art unit involved, the prosecution remains within a specific regulatory and technical framework. Practitioners can focus their strategy on the specific preferences and history of FERGUSON, JALISA HOLMES to navigate the pending action effectively. The concentration of the portfolio within the Biotechnology & Pharmaceuticals area allows for a consistent approach to the 1 pending office action.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| FERGUSON, JALISA HOLMES | 1 | 63.4% | +39.5% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17922795 | IMIDAZOLE 3-OXIDE DERIVATIVE BASED ACSS2 INHIBITORS AND METHODS OF USE THEREOF | FERGUSON, JALISA HOLMES | — |
| Art Unit | Apps |
|---|---|
| 1626 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17922795 | IMIDAZOLE 3-OXIDE DERIVATIVE BASED ACSS2 INHIBITORS AND METHODS OF USE THEREOF | FERGUSON, JALISA HOLMES | 1626 | §102§112DP | Final Rejection | — | Pending | Nov 02, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialEpivario Inc. has 1 pending office actions as of November 2026, spread across 1 art units and 1 examiners.
Jalisa Holmes Ferguson has the most, with 1 of Epivario Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.